AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 191 min read$DXCM

Brown Michael Jon sold $145K of DXCM

Brown Michael Jon (EVP Chief Legal Compliance Off) sold 1,700 shares of DEXCOM INC (DXCM) at $85.48 ($0.15M total) on 2026-10-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brown Michael Jon
Published Oct 19, 2026, 10:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 10:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$DXCM
Neutral
medium confidence
Mentioned
$DXCM
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DXCMNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly, but it provides a data point for monitoring insider sentiment.

02

Market read

A small insider sell with limited market impact; useful for tracking insider activity but not a catalyst for immediate price moves.

03

What to watch

Potential upcoming product announcements or regulatory news could offset any minor pressure from the insider sale.

Relevance 3/10Novelty 3/10Timing: after-hours filing

Background

Form 4 disclosures are primary sources for insider transactions and are routinely monitored by traders.

Company-level read

Ticker impact

$DXCMNeutralMedium confidence
Context

Officer Michael Brown sold 1,700 shares for $145,316 via a 10b5‑1 plan, reducing his stake to 98,185 shares.

Expected impact

likely modest downward pressure as the market prices the insider sell.

Evidence & confidence

The sale size is small relative to market cap and typical insider activity, so impact is limited.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be routine and not indicative of any negative outlook for Dexcom.

Key entities

  • Company
    Dexcom Inc.

    Medical device maker specializing in continuous glucose monitoring systems.

  • Executive
    Michael Brown

    Executive Vice President, Chief Legal Compliance Officer at Dexcom.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

DXCM insider trading history →

Related articles

OCT 28
$DXCMMed

A glucose sensor can be worn for up to 15.5 days. Dexcom's new monitor comes to Canada in November.

Dexcom's new G7 15 Day continuous glucose monitor, authorized by Health Canada, offers up to 15.5 days of wear and will be available in Canada in November. The company claims it is the longest-lasting and most accurate CGM system. Public and private reimbursement will be in place, making it accessible to eligible Canadians with diabetes. Dexcom aims to simplify glucose management with fewer sensor changes and reduced waste.

stocktitan.net4 min
OCT 14
$DXCMMedAI 8/10

A glucose monitor added about five hours a day in target blood sugar range for people with type 2 diabetes

Dexcom G7 CGM technology showed significant improvement in glucose control for Type 2 diabetes patients, reducing A1C levels by 1.6% on average. The study, published in NEJM, found users spent 5 more hours daily in target glucose range. Benefits were consistent across diverse participants, including those on GLP-1 medications, according to Dexcom.

stocktitan.net2 min
SEP 26
$DXCMMed

DexCom (DXCM) Tests Its Execution Story After Expanding Its CFO Role

DexCom (DXCM) promoted its CFO, Jereme Sylvain, to also serve as COO, expanding his role to include global operations and quality. The company's stock has seen volatility, with a 3.1% drop over the past week and a 30.2% gain year-to-date. Analysts suggest a fair value of $94.48, indicating a modest discount at the current price of $86.62.

simplywall.st2 min
SEP 19
$DXCMLow

Did COO Appointment Just Shift DexCom (DXCM) Investment Narrative?

DexCom (DXCM) appointed Jereme Sylvain as COO and Glenn Boehnlein to its board, focusing on execution, supply chain, and capital allocation. The company projects $6.8B revenue and $1.5B earnings by 2029, with analysts expecting 11.2% yearly growth. Investors watch leadership changes for impact on expansion and execution.

simplywall.st2 min